Skip to content

Effect of Beetroot Juice on Coronary Blood Flow and Walking Performance in PAD

Effects of Dietary Nitrate Supplementation on Coronary Blood Flow and Walking Performance in Peripheral Arterial Disease

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02553733
Acronym
HeartBeet
Enrollment
11
Registered
2015-09-18
Start date
2015-12-01
Completion date
2020-02-01
Last updated
2026-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Arterial Disease

Keywords

Dietary nitrate supplementation, Beetroot juice

Brief summary

In this study the investigators will test the hypothesis that short-term consumption of inorganic nitrate (supplied in concentrated beetroot juice) enhances coronary blood flow responses, large artery hemodynamics, and leg oxygenation/exercise tolerance in patients with peripheral arterial disease (PAD). Understanding and improving blood flow regulation in the heart and skeletal muscles of patients with PAD is important because exercise triggers symptoms of leg pain and substantially raises blood pressure and myocardial demand in these patients.

Detailed description

Peripheral arterial disease (PAD) is a strong predictor of cardiovascular mortality and negatively affects functional capacity and quality of life for as many as 14 million patients in the U.S. alone. One open-label study showed that acute consumption of beetroot juice improved 6 min walk performance, reduced blood pressure, and enhanced leg muscle oxygenation in PAD patients. However, no studies have rigorously confirmed these findings in a double-blind manner, nor have the effects of this supplement been investigated (acutely or short-term) in the coronary circulation of PAD patients. In addition to studying its effects on graded treadmill walking performance and consequent large artery vasodilation, the present study will examine the effects of short-term beetroot juice consumption (twice/day) on both coronary and leg vasodilator (graded calf flexion) and vasoconstrictor (isometric handgrip, voluntary apnea) responses in patients with PAD. Participants will randomly consume either nitrate-rich or nitrate-depleted beetroot juice with a 7 to 14 day wash-out period between. Effects of beetroot juice consumption on plasma nitrate, nitrite and methemoglobin will also be assessed.

Interventions

DRUGBeetroot juice

This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).

This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).

Sponsors

David N. Proctor, PhD
Lead SponsorOTHER
Milton S. Hershey Medical Center
CollaboratorOTHER
Wake Forest University Health Sciences
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
21 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Patients with peripheral arterial disease (PAD) 2. Capable of giving informed consent 3. Men and women age 21- 85 years 4. Diagnosed with PAD (i.e., ankle-brachial index below 0.9) 5. Fontaine stage II or less - no pain while resting 6. Satisfactory history and physical exam

Exclusion criteria

1. Children 2. Pregnant or nursing women 3. Patients taking nitroglycerine or nitrate preparations 4. Patients taking phosphodiesterase inhibitors such as sildenafil or tadalafil 5. Patients taking proton pump inhibitors 6. Ejection fraction \< 40% 7. Uncontrolled hypertension 8. Uncontrolled diabetes 9. Myocardial infarction within past 6 months or unstable angina 10. Severe lung disease (i.e., on supplemental oxygen or frequently use rescue inhalers) 11. Abnormality in hemoglobin or hematocrit or methemoglobin 12. Impaired renal function 13. Impaired liver function 14. History or diagnosis of Barrett's esophagus 15. Known allergy to beetroot juice or lemon juice 16. Inability to walk on a treadmill at a moderate pace (2.0 miles/hour)

Design outcomes

Primary

MeasureTime frameDescription
Peak Treadmill Time4 to 6 days after initiating daily ingestion of beetroot juicePeak treadmill time was determined using the Gardner treadmill protocol, measured as the number of seconds the participant was able to walk until they asked to stop the test due to leg fatigue.

Secondary

MeasureTime frameDescription
Coronary Flow Velocity Response to Peak Plantar Flexion Exercise4 days after initiating daily ingestion of beetroot juiceChange in LAD coronary artery flow velocity, measured using transthoracic ultrasound, from baseline rest to peak plantar flexion exercise. Single leg plantar flexion exercise of the most symptomatic leg was performed at a rate of 20 contractions per minute, with increases in workload (1 kg) every minute until volitional fatigue, or until maximum exercise duration of 14 min was reached.
Resting Blood Pressure4 to 6 days after initiating daily ingestion of beetroot juiceResting mean arterial blood pressure (mmHg) obtained prior to the exercise treadmill test obtained using an automated arm blood pressure cuff.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORUrs A Leuenberger, MD

Penn State University

Participant flow

Pre-assignment details

13 participants were screened for eligibility. 2 participants were excluded due to not meeting inclusion criteria. 11 participants were randomized. A total of 11 participants finished the entirety of the study (n=0 dropped out of the study once randomized).

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
5 Participants
Age, Categorical
Between 18 and 65 years
6 Participants
Age, Continuous64.5 years
STANDARD_DEVIATION 8
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
11 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Region of Enrollment
United States
11 participants
Sex: Female, Male
Female
2 Participants
Sex: Female, Male
Male
9 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 110 / 11
other
Total, other adverse events
0 / 110 / 11
serious
Total, serious adverse events
0 / 110 / 11

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 14, 2026